Abstract
BOLD CMR is a non-contrast approach for examining myocardial perfusion but despite major technical advancements to date, its reliability remains weak. A key reason for this is the unpredictable cardiac motion during stress, which can lead to pronounced artifacts that confound/ mask the true BOLD signal changes during hyperemia. Recently, regadenoson has become the vasodilator of choice owing to greater patient tolerability and ease of use. We hypothesized that at 10-mins post regadenoson administration (p.r.a), (a) BOLD CMR artifacts at stress are markedly reduced compared to those conventionally acquired at 2-mins p.r.a; and (b) that myocardial perfusion reserve (MPR) remains greater than 2.0 and is highly correlated with the BOLD effects estimated from T 2 maps.
Introduction
Myocardial Blood-Oxygen-Level-Dependent (BOLD) Cardiac Magnetic Resonance (CMR) represents a significant goal in cardiovascular imaging: the ability to assess heart muscle perfusion without external contrast agents. However, clinical adoption has been hindered by poor reliability, primarily due to cardiac motion artifacts during peak stress. When vasodilators like regadenoson are administered, the resulting rapid heart rate and unpredictable motion at peak stress (typically 2 minutes post-administration) often create image artifacts that obscure the physiological BOLD signal. This study explores "late-phase" imaging at 10 minutes post-administration as a solution to eliminate these artifacts while maintaining diagnostic accuracy.
Methods
The study utilized a canine model ($n=7$) and a hybrid PET/MR system for simultaneous data acquisition. PET imaging with $^{13}$N-ammonia served as the gold standard for quantifying Myocardial Blood Flow (MBF) and Myocardial Perfusion Reserve (MPR). The protocol compared baseline (rest) measurements with stress measurements taken at 2 minutes (peak stress) and 10 minutes (late stress) after regadenoson administration (2.5 $\mu$g/kg). Key metrics included Myocardial BOLD Variability (MBV) to quantify artifacts and Myocardial BOLD Response (MBR) to measure the physiological signal from $T_2$ maps.
Results
Artifact Mitigation
A critical finding was the dramatic reduction in image artifacts during the late phase. At 2 minutes post-administration, the Myocardial BOLD Variability (MBV) was significantly elevated ($1.6 \pm 0.9$), indicating substantial motion-induced noise. By 10 minutes, MBV returned to baseline levels ($1.0 \pm 0.3$), effectively providing a clear window for imaging.
Sustained Hyperemia and PET Validation
Despite the reduction in motion, the physiological hyperemic effect of regadenoson persisted into the late phase. At 10 minutes, MBF remained significantly higher than at rest ($1.8 \pm 0.9$ vs $0.6 \pm 0.3$ ml/g/min), with a mean MPR of 3.0—well above the clinical threshold of 2.0 for healthy tissue. Furthermore, the BOLD signal ($T_2$ values) at 10 minutes showed a strong correlation ($R = 0.7, p < 0.05$) with the PET-validated perfusion reserve.
Discussion and Conclusion
This study identifies a "sweet spot" in the timing of BOLD CMR following regadenoson administration. By waiting 10 minutes, researchers can bypass the turbulent motion of peak stress while still capturing a robust, PET-validated signal of myocardial perfusion. While these results are promising, the small sample size and the use of a canine model necessitate further validation in human clinical trials, particularly in patients with known Coronary Artery Disease (CAD), to confirm the diagnostic utility of late-phase BOLD CMR.
Summary updated